COMMUNIQUÉS West-GlobeNewswire

Saudi Arabia’s KFSHRC Continues to Rise as a Globally Renowned Medical Centre

09/02/2025 - 12:08

RIYADH, Saudi Arabia, Feb. 09, 2025 (GLOBE NEWSWIRE) -- Saudi Arabia’s King Faisal Specialist Hospital & Research Centre (KFSHRC) – the region’s top-ranked hospital – has secured 15th place in 2025 among the world’s [...]

Oculis Publishes Notifications of Transactions by Persons Discharging Managerial Responsibilities and Persons Closely Associated

08/02/2025 - 00:35

ZUG, Switzerland, Feb. 08, 2025 (GLOBE NEWSWIRE) -- The attached notifications relate to the vesting of earnout shares and associated removal of restrictions on these ordinary shares. Attachments Notification of [...]

MEDIA ADVISORY: Public healthcare advocates to protest at Minister of Health Sylvia Jones’ office

08/02/2025 - 02:09

SITUATION CRITICAL TORONTO, Feb. 07, 2025 (GLOBE NEWSWIRE) -- On Saturday February 8 th at 12 noon, the Grey Bruce, Brampton Caledon and Greater Toronto health coalitions, local chapters of the Ontario Health Coalition [...]

REPEAT - MEDIA ADVISORY: Public healthcare advocates to protest at Minister of Health Sylvia Jones’ office

08/02/2025 - 14:00

SITUATION CRITICAL TORONTO, Feb. 08, 2025 (GLOBE NEWSWIRE) -- On Saturday February 8 th at 12 noon, the Grey Bruce, Brampton Caledon and Greater Toronto health coalitions, local chapters of the Ontario Health Coalition [...]

4DMT Presents Positive 52-Week Results from Phase 2b Cohort of PRISM Wet AMD Study and Long-term Durability Data Supporting 4D-150 4FRONT Global Registration Program

08/02/2025 - 20:30

3E10 vg/eye achieved an 83% reduction in injection burden vs. projected on-label aflibercept 2 mg Q8W, 70% required 0-1 supplemental injection, and 57% were injection-free through 52 weeks In the recently diagnosed [...]

Three-Year Results for EYLEA HD® (aflibercept) Injection 8 mg in Patients with Wet Age-related Macular Degeneration Demonstrate Continued Durable Vision Gains and Anatomic Improvements with Extended Dosing Intervals

08/02/2025 - 21:55

At three years of EYLEA HD treatment, the vast majority of patients maintained visual and anatomic improvements while achieving extended dosing regimens, including those of just twice a year : 77%, 58%, 40% and 24% [...]

Firefly Neuroscience Congratulates Scientific Advisor, Dr. Christopher Wilson, Recipient of Prestigious UW Faculty of Engineering Award for Work on Superconducting Quantum Electronics

07/02/2025 - 13:30

- University of Waterloo’s Faculty of Engineering Recognizes Dr. Wilson with Faculty Research Excellence Award - - Esteemed researchers and engineers like Dr. Wilson are currently helping Firefly lay the groundwork for [...]

Kura Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

07/02/2025 - 13:30

SAN DIEGO, Feb. 07, 2025 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (the “Company”) (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of [...]

Matinas BioPharma Appoints Evelyn D’An to Board of Directors as Audit Committee Chair

07/02/2025 - 13:30

BEDMINSTER, N.J., Feb. 07, 2025 (GLOBE NEWSWIRE) -- Matinas BioPharma Holdings, Inc. (NYSE American: MTNB) today announced the appointment of Evelyn D’An to its Board of Directors as an independent director and Chair of [...]

Novo Nordisk A/S: Trading in Novo Nordisk shares by board members, executives and associated persons

07/02/2025 - 13:54

Trading in Novo Nordisk shares by board members, executives and associated persons Bagsværd, Denmark, 7 February 2025 — This company announcement discloses the data of the transaction(s) made in Novo Nordisk shares by [...]

Neuronetics Announces Pricing of $18 Million Underwritten Public Offering of Common Stock

07/02/2025 - 13:54

MALVERN, Pa., Feb. 07, 2025 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ: STIM) (the “Company”) today announced that it has priced its previously announced underwritten public offering of its common stock, comprised of [...]

Conduit Pharmaceuticals Transitions to Phase II of Sarborg Collaboration to Support AI-Driven Drug Development

07/02/2025 - 14:00

Conduit and Sarborg complete all milestones of Phase I of their AI-driven drug development collaboration, and commence transitioning to Phase II, which will focus on developing personalized software dashboards to [...]

PROCEPT BioRobotics® to Report Fourth Quarter 2024 Financial Results on February 25, 2025 and Attend the TD Cowen 45th Annual Healthcare Conference and the 2025 Leerink Partners Healthcare Conference

07/02/2025 - 14:00

SAN JOSE, Calif., Feb. 07, 2025 (GLOBE NEWSWIRE) -- PROCEPT BioRobotics (Nasdaq: PRCT) (the “Company”), a surgical robotics company focused on advancing patient care by developing transformative solutions in urology, [...]

ITM to Present at Oppenheimer’s 35th Annual Healthcare Life Sciences Conference

07/02/2025 - 14:00

Garching / Munich, February 7, 2025 – ITM Isotope Technologies Munich SE (ITM), a leading radiopharmaceutical biotech company, today announced its participation in Oppenheimer’s 35 th Annual Healthcare Life Sciences [...]

Annovis to Present at Oppenheimer's 35th Annual Healthcare Life Sciences Conference

07/02/2025 - 14:00

MALVERN, Pa., Feb. 07, 2025 (GLOBE NEWSWIRE) -- via IBN – Annovis Bio Inc. (NYSE: ANVS) ("Annovis" or the "Company"), a late-stage clinical drug platform company pioneering transformative therapies for neurodegenerative [...]

Medera, Inc. to Participate in Two Upcoming Investor Conferences

07/02/2025 - 14:00

SUMMIT, N.J. and BOSTON, Feb. 07, 2025 (GLOBE NEWSWIRE) -- Medera, Inc., (“Medera”), a clinical-stage biotechnology company, announced today that the management team will participate in the two upcoming investor [...]

Processa Pharmaceuticals to Present at the 2025 BIO CEO & Investor Conference

07/02/2025 - 14:00

HANOVER, Md., Feb. 07, 2025 (GLOBE NEWSWIRE) -- Processa Pharmaceuticals, Inc. (Nasdaq: PCSA) (Processa or the Company), a clinical-stage pharmaceutical company focused on developing the next generation cancer therapies [...]

Maze Therapeutics Doses First Patient in Phase 2 HORIZON Clinical Trial Evaluating MZE829 as a Potential Treatment for APOL1 Kidney Disease

07/02/2025 - 14:00

SOUTH SAN FRANCISCO, Calif., Feb. 07, 2025 (GLOBE NEWSWIRE) -- Maze Therapeutics, Inc. (Nasdaq: MAZE), a clinical-stage biopharmaceutical company harnessing the power of human genetics to develop novel, small molecule [...]

Nusano to Present at Oppenheimer 35th Annual Healthcare Life Sciences Conference

07/02/2025 - 14:00

WEST VALLEY CITY, Utah, Feb. 07, 2025 (GLOBE NEWSWIRE) -- Nusano, a physics company transforming the production of radioisotopes, today announced the company’s CFO Pushkar Bedekar will present at Oppenheimer’s 35th [...]